ArticleJournal of medical biochemistry2026
Correlation analysis of FABP3, MCP-4, and CXCL9 levels and myocardial damage in patients with severe pneumonia.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the correlations between the levelsof serum monocyte chemoattractant protein-4 (MCP-4),heart-type fatty acid binding protein (FABP3), andchemokine ligand 9 (CXCL9) and myocardial damage insevere mycoplasma pneumonia (SMPP) patients. Methods: A total of 158 patients with severe mycoplasmapneumonia complicated with myocardial damage wereincluded in the SMPP group. They were divided into amyocardial damage group (n=42) and a nonmyocardialdamage group (n = 116) according to whether myocardialdamage occurred. The control group consisted of an additional 102 healthy people who were examined throughoutthe same time period. The levels of serum MCP-4, FABP3and CXCL9 in the two groups were compared. The patients'general clinical data were recorded. Multivariate logisticregression was used to identify risk factors for myocardialinjury in patients with severe mycoplasma pneumonia. Results: The levels of serum MCP-4, FABP3 and CXCL9 inthe SMPP group were significantly greater (all P<0.05).Compared with those in the nonmyocardial damage group,serum MCP-4, FABP3, and CXCL9 levels were considerablyhigher (all P< 0.05) in the group with myocardial injury Age, sex, diabetes, smoking history, hypoxemia, jaundice,and chronic obstructive pulmonary disease (COPD) did notdiffer statistically significantly between the two groups (allP> 0.05). Compared with those in the nonmyocardial damage group, the proportions of patients with hypertension,coronary heart disease, and anaemia, as well as the levelsof serum MCP-4, FABP3, and CXC L9, in the myocardialdamage group were significantly higher (all P<0.05).Combined hypertension, coronary heart disease, anaemia,and high levels of serum MCP-4, FABP3, and CXCL9 arerisk factors for myocardial damage in patients with severemycoplasma infection. The levels of serum MCP-4, FABP3and CXCL9 in patients were positively correlated with theincidence of myocardial damage in patients with severemycoplasma infection (all P< 0.05). Conclusions: The levels of serum MCP-4, FABP3 and CXCL9are positively correlated with myocardial damage in patientswith severe mycoplasma pneumonia. Moreover, combinedhypertension, coronary heart disease, anaemia and high levels of serum MCP-4, FABP3 and CXCL9 are risk factors formyocardial damage in patients with severe mycoplasma infection. These three factors can serve as biological indicatorsof myocardial damage in patients with severe mycoplasmainfection in clinical practice and are highly important forassessing patients' conditions and formulating treatmentplans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.